Prepared by MERRILL CORPORATION www.edgaradvantage.com




QuickLinks
 -- Click here to rapidly navigate through this document
  



Exhibit 10.14

Confidential treatment requested  


  
 

    DEVELOPMENT AGREEMENT    
  


    This Agreement is made and entered into on this 20th day of July, 1999 ("Effective Date") between
Seattle Genetics, Inc. ("Seattle Genetics"), a Delaware corporation with offices at 22215 26th Avenue, Bothell, WA 98021 and GTC
Corporation ("GTC"), a Massachusetts corporation with offices at 175 Crossing Boulevard, Framingham, MA 01701-9322. 


    Whereas,
Seattle Genetics and GTC agree to collaborate under the following terms and conditions on the further development of humanized huBR96-2 mAb with the intent of
determining the clinical and commercial potential for this version of BR96. In consideration of the mutual promises and covenants set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 



	1.
	GTC
will prepare up to [*] ([*])[*] of transgenic humanized BR96-2 monoclonal antibody ("tg
huBR96-2 mAb") research grade from the milk of transgenic goats and purified by, captured by and eluted from a Protein A affinity chromatography column for delivery to Seattle Genetics.
GTC will use reasonable commercial efforts to deliver such tg huBR96-2 mAb to Seattle Genetics within [*] ([*]) months of the date hereof.



	2.
	Seattle
Genetics will evaluate the potential efficacy of tg huBR96-2 mAb and if Seattle Genetics determines that tg huBR96-2 mAb should enter development,
then Seattle Genetics will evaluate the safety of a second generation BR96 antibody-drug conjugate based on the tg huBR96-2 mAb using appropriate pre-clinical
models as determined by Seattle Genetics.



	3.
	In
the event Seattle Genetics decides to continue with the clinical development and based on the clinical results decides to proceed with the commercial use of a second generation
BR96 product based on tg huBR96-2 mAb, Seattle Genetics agrees that GTC will be the exclusive manufacturer and supplier of tg huBR96-2 mAb. The parties shall use good faith
effort to enter into agreement(s) for the manufacturing and delivery of tg huBR96-2 mAb, as appropriate for the pre-clinical, clinical and commercialization needs. The
agreement(s) will contain reasonable commercial terms customary in the industry and as mutually agreed upon by the parties.



	4.
	It
is estimated that Seattle Genetics will be in a position to make a [*] decision regarding development of tg huBR96-2 mAb within
[*] ([*]) [*] of receipt of the [*] ([*])[*] of tg
huBR96-2 mAb.



	5.
	In
the event that Seattle Genetics makes the decision to discontinue the development of tg huBR96-2 mAb and decides to continue with the development of huBR96-2 mAb derived from an
alternative expression system and GTC has delivered the [*] ([*]) [*] of tg huBR96-2 mAb Settle Genetics agrees to
pay GTC $[*]. 




    Seattle
Genetics and GTC represent to one another that they have the right to enter into this Agreement, as well as the right to further develop and commercialize tg
huBR96-2 mAb as contemplated by this Agreement. 


    EXCEPT AS SET FORTH ABOVE, THE PARTIES EXCLUDE FROM THIS AGREEMENT ALL REPRESENTATIONS AND WARRANTIES INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF
MERCHANTAB1LITY AND OF FITNESS FOR A PARTICULAR PURPOSE.  


[*]   Confidential treatment requested 


1





 


    Seattle Genetics and GTC anticipate that they will exchange proprietary and confidential information during the term of this Agreement. The use and disclosure of such information is
governed by the agreement of the panics pertaining to confidentiality, executed by the panics on or before the date of this Agreement
("Non-Disclosure"), a copy of which is attached hereto as Exhibit A. 



    This
Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, excluding its principles relating to conflict of laws. 


    In
witness whereof, the parties have caused this Agreement to be executed by their authorized representatives, to be effective as of the Effective Date above. 



	GENZYME TRANSGENICS CORPORATION	 	 
	

By:	
 	

/s/ MICHAEL W. YOUNG   
	
 	

 
	Name:	 	Michael W. Young	 	 
	Title:	 	V.P. Commercial Development	 	 
	Date:	 	16 July 1999	 	 
	
SEATTLE GENETICS, INC.	
 	

 
	

By:	
 	

/s/ H. PERRY FELL   
	
 	

 
	Name:	 	H. Perry Fell	 	 
	Title:	 	President	 	 
	Date:	 	7-20-99	 	 




2









QuickLinks


DEVELOPMENT AGREEMENT